Erlotinib in non-small cell lung cancer

Masayuki Takeda, Isamu Okamoto

Research output: Contribution to journalArticlepeer-review


Erlotinib and gefitinib are quinazoline derivatives that selectively and reversibly inhibit the tyrosine kinase activity of the EGFR. Activating mutations in the EGFR confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. Erlotinib has been developed in EGFR mutation-positive patients as a first-line treatment, and results from recently completed phase III studies have shown superior progression-free survival and response rates for erlotinib, compared to chemotherapy.

Original languageEnglish
Pages (from-to)896-900
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Issue number6
Publication statusPublished - Jun 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Erlotinib in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this